EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

BACKGROUND: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence of these events and the lack of guidance for rheumatologists addressing them, a European League Against...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostine, Marie, Finckh, Axel, Bingham, Clifton O, Visser, Karen, Leipe, Jan, Schulze-Koops, Hendrik, Choy, Ernest H, Benesova, Karolina, Radstake, Timothy R D J, Cope, Andrew P, Lambotte, Olivier, Gottenberg, Jacques-Eric, Allenbach, Yves, Visser, Marianne, Rusthoven, Cindy, Thomasen, Lone, Jamal, Shahin, Marabelle, Aurélien, Larkin, James, Haanen, John B A G, Calabrese, Leonard H, Mariette, Xavier, Schaeverbeke, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Recommendation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788064/
https://www.ncbi.nlm.nih.gov/pubmed/32327425
http://dx.doi.org/10.1136/annrheumdis-2020-217139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788064/
https://www.ncbi.nlm.nih.gov/pubmed/32327425
http://dx.doi.org/10.1136/annrheumdis-2020-217139

Ejemplares similares